Pneumagen Announces Appointment of John Beadle as Non-Executive Director
St Andrews, UK – 10 May 2022 - Pneumagen, a clinical stage biotech company developing Neumifil, a novel intranasal spray which is designed to provide patients at risk with an easy to use, pan-anti-viral treatment to reduce, prevent and manage respiratory disease exacerbations caused by viral infections, announces the appointment of Dr. John Beadle, Founder and former Chief Executive Officer of PsiOxus Therapeutics Ltd, as a Non-Executive director of the company.
Douglas Thomson, CEO of Pneumagen, commented “I am delighted that we have been able to attract someone of John’s calibre to join Pneumagen’s Board. His successful career founding, funding and growing innovative biotech companies will provide invaluable experience to Pneumagen at this key time in our development as we advance the clinical studies of Neumifil. I look forward to accessing John’s experience and counsel, alongside the other members of our Board.”
John Beadle is a highly entrepreneurial CEO and leader with broad experience in building successful innovation driven biotechnology companies. During his career, he has helped build and worked with strong management teams to deliver exceptional scientific, clinical and commercial results.
John has a strong medical and business background (MD MBA) and has led innovative leading-edge companies and programs across several ATMP (Advanced Therapy Medicinal Products) fields including nucleotide-based vaccines, stem cell therapies, gene therapies and immuno-oncology.
His most recent role was as Founding CEO of PsiOxus, a clinical stage oncology company pioneering systemic immune oncology products designed to drive sustained reprogramming of the tumor microenvironment to overcome resistance to therapy. His previous roles include Founder and Chief Medical Officer of PowderMed; Entrepreneur in Residence at Imperial College, London; Site Head at Pfizer; and Vice President of Global Medical Operations at GlaxoSmithKline.
John Beadle added “I believe that Pneumagen can make a significant difference to the treatment of viral respiratory tract infections with its world-class science, strong IP and highly experienced management team. Neumifil represents a truly innovative, pan-viral treatment approach for patients at risk of viral induced exacerbations in a world where, as we know only too well, the threat from infectious diseases is significant and where access to new effective anti-virals is clearly needed.”
John received his medical degree from the University of the Witwatersrand in South Africa, a DA, Anaesthesia from the South African College of Medicine, and an MBA from the London Business School.
